Ecuador Registration Exemption Scope: Low-Risk Devices and Obligation Boundaries

1. Key takeaways

Exemption from registration in Ecuador is strictly enumerated: Article 29 of the new regulation lists 5 categories (custom-made devices, research-purpose devices, integral parts and components, control software without an independent medical purpose, and refurbished or remanufactured devices), and Article 30 sets 2 categories of refusal red lines. General provision QUINTA provides that low-risk devices and condoms may be commercialized freely, yet they must still comply with the requirements of this regulation and of the Ley Organica de Salud — free commercialization is not an exemption from obligations.

2. Legal basis

Substance of general provision QUINTA: low-risk devices and condoms may be commercialized freely; however, they are obligated to comply with the requirements laid down in this regulation and in the Ley Organica de Salud.

3. Expert insights

Insight one: the proviso in general provision QUINTA is the key to understanding the exemption. The first half addresses sale without a registration certificate; the second half states that all other obligations continue to apply, including labeling (Articles 48 to 52), operating permits (Article 60), good practices (general provision SEXTA) and vigilance (Article 70). Reading the provision as a blanket carve-out is the most dangerous misinterpretation.

Insight two: the concrete scope of low risk is not defined, and this is a genuine uncertainty of the transition period. Article 21 defines Class I as Riesgo Bajo (low risk), and general provision QUINTA uses the phrase low-risk devices, yet the new regulation never states in its operative text whether low risk equals Class I, nor does it delimit the product categories covered beyond condoms. This boundary must await subsequent ARCSA instructivos; during the transition, the safer practical estimate is to proceed on the assumption that everything requires registration.

Insight three: the conditions of Article 29 (c) stack four requirements. To enjoy the exemption, accessories, components, parts and spare parts must simultaneously form an integral part of the device, be exclusively dedicated to its established intended purpose, and be stated in the instructions for use or the user manual, plus one negative condition: not commercialized separately and with no independent intended purpose. Missing any one of the four forfeits the exemption.

Insight four: Article 29 (e) places refurbishment and remanufacturing outside the registration system, but not into free sale. Devices that have been modified or remanufactured, meaning devices whose original manufacture has been altered by a process, are exempt from registration; their circulation remains subject to other rules, and the red lines of Article 30 apply equally.

Insight five: the two red lines of Article 30 are absolute refusals, and they have a time dimension. (a) devices containing ingredients prohibited nationally or internationally, as published in the ARCSA list; (b) devices under standing health alerts. The practical meaning of item (b) is that a device free of alerts at submission but placed under an alert during review will trigger refusal.

4. Practical recommendations

1. During the transition, apply the conservative practical estimate that everything requires registration: do not abandon registration early on the basis of general provision QUINTA.
2. Check exported parts and components against all four conditions of Article 29 (c): missing any one means applying for an independent registration.
3. Track subsequent ARCSA instructivos on the scope of low-risk devices: adjust the submission strategy only once a clear position is issued.
4. Screen prohibited ingredient lists at the material and formulation design stage and re-check alert status monthly.
5. Even for exempt products, complete the labeling, operating permit, good practices and vigilance obligations: the compliance system must not be abandoned as a whole.

5. Verification checklist

• □ All 5 exemption categories of Article 29 have been checked item by item
• □ Parts and components have been confirmed to satisfy all four conditions of Article 29 (c)
• □ Products have been confirmed free of nationally or internationally prohibited ingredients
• □ Products have been confirmed free of standing health alerts, both before submission and during review
• □ Exempt products have still completed the labeling, operating permit and good practice obligations
• □ Subsequent ARCSA instructivos on the scope of low-risk devices are being tracked

Regulatory information verified as of October 29, 2026

GRZAN core service lines

1. Global registration access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, together with pre-market registration pathway planning and submission execution across Latin America, Southeast Asia and the Middle East.
2. Authorized representative services: EU EC REP, UK RP, Swiss CH REP, Australian sponsor and US Agent holding and representation services, with support for neutral license-holder structures.
3. Quality system compliance: ISO 13485 establishment and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) drafting and remediation.
4. Clinical and evaluation support: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
5. Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why manufacturers choose GRZAN

• Local regulatory teams: target-market work is performed by locally licensed regulatory professionals, and submission dossiers are written directly in the local official language without secondary translation.
• Neutral license-holder structures: GRZAN offers holding arrangements that are not tied to any distribution channel, preventing registration certificates from being locked in by channel partners.
• Regional leverage: one technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance costs.
• Full lifecycle support: from classification determination and pathway design through dossier preparation, license holding, customs clearance, post-market vigilance and renewal.

Contact

• GRZAN provides registration support in Ecuador for manufacturers, importers and authorized representatives.
• Email: info@grzanglobal.com
• Service inquiries: Ecuador and Andean market registration plans, license-holder structure design, official fee and timeline estimation